- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens | 1 | Investing.com | ||
| Di | Prelude Therapeutics Inc - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor | 108 | GlobeNewswire (Europe) | WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| 09.01. | Prelude Therapeutics Inc - 8-K, Current Report | - | SEC Filings | ||
| 06.12.25 | Prelude Therapeutics, Incorporated: Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs | 5 | GlobeNewswire (USA) | ||
| 14.11.25 | Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens | 14 | Investing.com | ||
| 12.11.25 | Prelude Therapeutics Inc Q3 Loss Decreases, Beats Estimates | 8 | RTTNews | ||
| 12.11.25 | Prelude Therapeutics, Incorporated: Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 182 | GlobeNewswire (Europe) | Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing... ► Artikel lesen | |
| PRELUDE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Prelude Therapeutics Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Prelude Therapeutics Inc - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | Prelude Therapeutics pauses clinical development of SMARCA2 degrader program | 7 | Seeking Alpha | ||
| 04.11.25 | Prelude Therapeutics Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 04.11.25 | Prelude Therapeutics shifts focus to JAK2 and KAT6A programs | 3 | Investing.com | ||
| 04.11.25 | Prelude Therapeutics, Incorporated: Prelude Therapeutics Announces Strategic Business Update | 232 | GlobeNewswire (Europe) | Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F... ► Artikel lesen | |
| 04.11.25 | Prelude Therapeutics, Incorporated: Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors | 312 | GlobeNewswire (Europe) | Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients... ► Artikel lesen | |
| 03.11.25 | Prelude Therapeutics, Incorporated: Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 17.10.25 | Prelude Therapeutics appoints Katina Dorton to board of directors | 1 | Investing.com | ||
| 17.10.25 | Prelude Therapeutics Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10.25 | Prelude Therapeutics, Incorporated: Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors | 2 | GlobeNewswire (USA) | ||
| 23.09.25 | H.C. Wainwright bekräftigt Kaufempfehlung für Prelude Therapeutics mit Kursziel von 5 $ | 3 | Investing.com Deutsch |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| EVOTEC | 6,148 | +0,79 % | SDAX: Evotec-Aktie schießt zweistellig nach oben | Eine Kaufempfehlung von Berenberg entfacht neuen Optimismus bei Evotec und katapultiert die Biotech-Aktie an die Indexspitze. Die Aktie der Evotec hat am Dienstagmittag ein Kursfeuerwerk gezündet und... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| AMGEN | 325,15 | +0,06 % | Märkte am Morgen: "KI-Realitätscheck", Wolters Kluwer, AMD, Amgen, Walmart, Novo Nordisk | Die Stimmung an den Aktienmärkten ist derzeit sehr, sehr wechselhaft. Das war gestern deutlich zu spüren. Der DAX war bemerkenswert stark in den Handel gestartet, schloss allerdings leicht im Minus.... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| BIOFRONTERA | 2,420 | -1,22 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| BIOXXMED | 1,328 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,365 | -0,27 % | Defence Therapeutics Inc.: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform | Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,411 | -3,52 % | Breaking News: Tycoon für den Vorstand von NurExone! | ||
| ABIVAX | 98,30 | -0,30 % | ABIVAX Société Anonyme (ABVX): A Bull Case Theory | ||
| IBIO | 1,740 | -14,71 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 56,04 | +2,75 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| TME PHARMA | 0,065 | 0,00 % | TME Pharma NV: TME Pharma provides update on its activities | TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,126 | +0,51 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen |
Das Unternehmen PRELUDE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,150 (+7,43 %) liegt der Kurs bei 2,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRELUDE THERAPEUTICS INC finden Sie auf Wallstreet Online.